Back to results
US 2015/0306076 A1Published application
Tazobactam arginine antibiotic compositions
AssigneeCubist Pharmaceuticals, Inc.
InventorsJan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions.
Claims22
1-7. (canceled)
A method of making a pharmaceutical composition comprising combining crystalline tazobactam arginine and a beta-lactam compound.
25-48. (canceled)
A method of making a pharmaceutical composition, comprising combining crystalline tazobactam arginine and a beta-lactam compound,
- wherein the crystalline tazobactam arginine is characterized by an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-Theta at angles of about 8.9°±0.3°, about 18.0°±0.3° and about 21.2°±0.3°, and
- wherein the beta-lactam compound is (6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, or a pharmaceutically acceptable isomer, salt, ester, hydrate, solvate, or combination thereof.
A method of making a pharmaceutical composition, comprising the steps of:
- (1) preparing an aqueous solution comprising crystalline tazobactam arginine and a beta-lactam compound,
- wherein the crystalline tazobactam arginine is characterized by an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-Theta at angles of about 8.9°±0.3°, about 18.0°±0.3° and about 21.2°±0.3°, and
- wherein the beta-lactam compound is (6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, or a pharmaceutically acceptable isomer, salt, ester, hydrate, solvate, or combination thereof;
- and
- (2) lyophilizing the solution to obtain said pharmaceutical composition.
2 more elements
Dependencies are inferred from the claim text.